Evidence map›Paper›PMID 38669521›Full record

ArticleCancer biomarkers : section A of Disease markers2025

Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC.

Nozomu Kimura, Yoko Tsukita, Risa Ebina-Shibuya, Eisaku Miyauchi, Mitsuhiro Yamada, Daisuke Narita, Ryota Saito, Chihiro Inoue, Naoya Fujino, Tomohiro Ichikawa and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Nozomu KimuraDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yoko TsukitaDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Risa Ebina-ShibuyaDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Eisaku MiyauchiDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Mitsuhiro YamadaDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Daisuke NaritaDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Ryota SaitoDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Chihiro InoueDepartment of Anatomic Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Naoya FujinoDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tomohiro IchikawaDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tsutomu TamadaDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hisatoshi SugiuraDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUNDBiomarkers predicting clinical outcomes of treating non-small cell lung cancer (NSCLC) with combination of immune checkpoint inhibitors (ICIs) and chemotherapy would be valuable.OBJECTIVEThis study aims to seek predictors of combination of ICI/chemotherapy response in NSCLC patients using peripheral blood samples.METHODSPatients diagnosed with advanced NSCLC between July 2019 and May 2021 receiving combination of ICI/chemotherapy were included and assessed for partial responses (PR), stable disease (SD) or progressive disease (PD). We measured circulating immune cells, plasma cytokines and chemokines.RESULTSNineteen patients were enrolled. The proportions of circulating natural killer (NK) cells within CD45

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung NeoplasmsAdultAgedFemaleHumansKiller Cells, NaturalMaleMiddle AgedPrognosisBiomarkers, TumorImmune Checkpoint InhibitorsCD4 + cellsCombination of chemotherapy and immune checkpoint inhibitorCXCL10natural killer cellsNSCLC

Identifiers

PMID38669521
PMCPMC12288547
OpenAlexW4395678820

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.